NCT00611884已完成2 期
A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 245
- 试验地点
- 1
- 主要终点
- Change in Glycosylated Haemoglobin (HbA1c)
研究概览
简要总结
This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)
- •Insulin naïve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximeum 14 days within the last 3 months)
- •Treatment with one or two oral anti-diabetic drug (OADs): metformin, sulphonylurea (SU) (or other insulin secretagogue e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to the summary of product characteristics (SPC) or locally approved PI
- •HbA1c 7.0-11.0 % (both inclusive)
- •Body Mass Index (BMI) 23-42 kg/m^2 [lb/in^2 x 703] (both inclusive)
排除标准
- •Metformin contraindication according to local practice
- •Thiazolidinedione (TZD) treatment within previous three months prior to visit 1
- •Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) three months prior to randomisation
- •Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system (except for conditions associated with type 2 diabetes) that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial drug
研究组 & 干预措施
SIBA (D)
Experimental
干预措施: metformin (Drug)
SIBA (D)
Experimental
干预措施: insulin degludec (Drug)
SIBA (E)
Experimental
干预措施: insulin degludec (Drug)
SIBA (E)
Experimental
干预措施: metformin (Drug)
SIBA (D) M, W, F
Experimental
干预措施: insulin degludec (Drug)
SIBA (D) M, W, F
Experimental
干预措施: metformin (Drug)
IGlar
Active Comparator
干预措施: insulin glargine (Drug)
IGlar
Active Comparator
干预措施: metformin (Drug)
结局指标
主要结局
Change in Glycosylated Haemoglobin (HbA1c)
时间窗: Week 0, Week 16
Change from baseline in HbA1c after 16 weeks of treatment
次要结局
- Rate of Major and Minor Hypoglycaemic Episodes(Week 0 to Week 16 + 5 days follow up)
- Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)(Week -4, Week 16)
- Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)(Week -4, Week 16)
- Vital Signs: Diastolic Blood Pressure (BP)(Week 0, Week 16)
- Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)(Week 16)
- Rate of Nocturnal Major and Minor Hypoglycaemic Episodes(Week 0 to Week 16 + 5 days follow up)
- Rate of Treatment Emergent Adverse Events (AEs)(Week 0 to Week 16 + 5 days follow up)
- Vital Signs: Pulse(Week 0, Week 16)
- Physical Examination(Week -4, Week 0, Week 8, Week 16)
- Laboratory Safety Parameters (Biochemistry): Serum Creatinine(Week -4, Week 16)
- Vital Signs: Systolic Blood Pressure (BP)(Week 0, Week 16)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01513590Novo Nordisk A/S394
已完成
3 期
Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00474045Novo Nordisk A/S470
已完成
3 期
Comparison of NN1250 With Insulin Glargine in Type 2 DiabetesDiabetes Mellitus, Type 2DiabetesNCT01006291Novo Nordisk A/S687
已完成
3 期
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 DiabetesDiabetes Mellitus, Type 2DiabetesNCT01562561Novo Nordisk A/S213
已完成
2 期
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsAcquired Bleeding DisorderTraumaNCT01563523Novo Nordisk A/S283